Multicentre, Single Arm, Open Label, Non Controlled Phase IV Clinical Trial to Evaluate Safety of Cabazitaxel (Jevtana) in Combination With Oral Prednisone (or Prednisolone) for the Treatment of Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen
Phase of Trial: Phase IV
Latest Information Update: 16 Jan 2018
Price : $35 *
At a glance
- Drugs Cabazitaxel (Primary) ; Prednisolone; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Sanofi; Sanofi-Synthelabo
- 31 Aug 2018 Biomarkers information updated
- 01 Jun 2016 Status changed from active, no longer recruiting to completed.
- 03 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 Jul 2016, according to ClinicalTrials.gov record.